Craft

Cipla

Stock Price

₹1.3 K

2024-04-19

Market Capitalization

₹1.1 T

2024-04-19

Revenue

₹224.7 B

FY, 2023

Cipla Summary

Company Summary

Overview
Cipla is a global pharmaceutical company, which offers active pharmaceutical ingredients and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The Company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals.
Type
Public
Status
Active
Founded
1935
HQ
Mumbai, IN | view all locations
Website
http://www.cipla.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Umang Vohra

    Umang Vohra, Managing Director & Global Chief Executive Officer

  • Philippe Malecki

    Philippe Malecki, Regional Head APAC

  • Anchal Sultania

    Anchal Sultania, Business Head - Europe and Russia CIS

  • Anand Agarwal

    Anand Agarwal, Regional Head - MEPAC

LocationsView all

13 locations detected

  • Mumbai, MH HQ

    India

    1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel

  • Central Islip, NY

    United States

    550 S Research Pl

  • South Melbourne, VIC

    Australia

    Level 1/132 Albert Rd

  • Mumbai, MH

    India

    2nd Floor, Bldg, 5, LBS Rd, Suryanagar No. 2, HMPL Surya Nagar, Vikhroli West

  • Nairobi, Nairobi County

    Kenya

    Chiromo Road Purshottam Place

  • Cape Town, WC

    South Africa

    Mispel Street, Bellville

and 7 others

Cipla Financials

Summary Financials

Revenue (Q3, 2024)
₹65.1B
Gross profit (Q3, 2024)
₹45.7B
Net income (Q3, 2024)
₹10.7B
Cash (Q2, 2024)
₹11.8B
EBIT (Q3, 2024)
₹15.0B
Enterprise value
$1.1T

Blogs

Footer menu